The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients
Cancer Medicine · 2024
DOI: 10.1002/cam4.7364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Haitao Ge und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Brain Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heilongjiang Province Postdoctoral Fund, Haiyan Fund of Cancer Hospital Affiliated to Harbin Medical University, China Postdoctoral Science Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Lung cancer (LC) and breast cancer (BC) are the most common causes of brain metastases (BMs). Time from primary diagnosis to BM (TPDBM) refers to the time interval between initial LC or BC diagnosis and development of BM. This research aims to identify clinical, molecular, and therapeutic risk factors associated with shorter TPDBM.
Methods
We retrospectively reviewed all diagnosed LC and BC patients with BM at Harbin Medical University Cancer Hospital from 2016 to 2020. A total of 570 patients with LC brain metastasis (LCBM) and 173 patients with breast cancer brain metastasis (BCBM) patients who met the inclusion criteria were enrolled for further analysis. BM free survival time curves were generated using Kaplan–Meier analyses. Univariate and multivariate Cox regression analyses were applied to identify risk factors associated with earlier development of BM in LC and BC, respectively.
Results
The median TPDBM was 5.3 months in LC and 44.4 months in BC. In multivariate analysis, clinical stage IV and M1 stage were independent risk factors for early development of LCBM. LC patients who received chemotherapy, targeted therapy, pulmonary radiotherapy, and pulmonary surgery had longer TPDBM. For BC patients, age ≥ 50 years, Ki67 ≥ 0.3, HER2 positive or triple‐negative breast cancer subtype, advanced N stage, and no mastectomy were correlated with shorter TPDBM.
Conclusions
This single‐institutional study helps identify patients who have a high risk of developing BM early. For these patients, early detection and intervention could have clinical benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
- Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, China.
- Harbin Medical University, Harbin, China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Chunyang Liu, Peng Liang, Hongbo Bao
Förderung
- Heilongjiang Province Postdoctoral Fund
- Haiyan Fund of Cancer Hospital Affiliated to Harbin Medical University
- China Postdoctoral Science Foundation
- Science and Technology Plan of Heilongjiang Provincial Health Commission
Zitieren
APA
Ge, H., Zhu, K., Sun, Q., Wang, H., Liu, H., Ge, J., Liu, C., Liang, P., Lv, Z., & Bao, H. (2024). The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients. Cancer Medicine. https://doi.org/10.1002/cam4.7364
Vancouver
Ge H, Zhu K, Sun Q, Wang H, Liu H, Ge J, et al. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients. Cancer Medicine. 2024. doi:10.1002/cam4.7364
BibTeX
@article{Ge2024,
author = {Ge, Haitao and Zhu, Kaibin and Sun, Qian and Wang, Huan and Liu, Hui and Ge, Jinyi and Liu, Chunyang and Liang, Peng and Lv, Zhonghua and Bao, Hongbo},
title = {The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7364}
}
EUVIMED